4D Molecular Therapeutics Reports Positive Interim Trial Results

An announcement from 4D Molecular Therapeutics ( (FDMT) ) is now available.

On November 6, 2025, 4D Molecular Therapeutics announced positive interim results from their Phase 1/2 PRISM clinical trial for 4D-150, a treatment for wet age-related macular degeneration (wet AMD). The data, collected up to August 22, 2025, shows that 4D-150 effectively maintains visual acuity and controls retinal anatomy, while significantly reducing the treatment burden through fewer anti-VEGF injections over a period of up to two years. The trial’s results suggest durable disease control and favorable safety outcomes, positioning 4D-150 as a promising therapeutic option in the ophthalmology market.

The most recent analyst rating on (FDMT) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on 4D Molecular Therapeutics stock, see the FDMT Stock Forecast page.

Spark’s Take on FDMT Stock

According to Spark, TipRanks’ AI Analyst, FDMT is a Neutral.

The overall stock score is primarily influenced by the company’s financial performance challenges, which are typical for early-stage biotech firms. Despite these challenges, the stock shows strong technical momentum, suggesting positive market sentiment. However, the lack of profitability and absence of dividends weigh down the valuation score.

To see Spark’s full report on FDMT stock, click here.

More about 4D Molecular Therapeutics

4D Molecular Therapeutics operates in the biotechnology industry, focusing on the development of genetic medicines. The company specializes in creating transformative therapies for patients with severe genetic diseases, with a particular emphasis on ophthalmology.

Average Trading Volume: 776,897

Technical Sentiment Signal: Buy

Current Market Cap: $502.1M

For an in-depth examination of FDMT stock, go to TipRanks’ Overview page.